CoChat

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

Open access
Gao, Jing, Wang, Wei-qi, Pei, Qing, Lord, Megan S., Yu, Hai-jun · 2020 · Acta Pharmacologica Sinica

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Abstract

Current cancer immunotherapy has limited response rates in a large variety of solid tumors partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor microenvironment (ITM). A number of clinical cancer treatment modalities, including radiotherapy, chemotherapy, photothermal and photodynamic therapy, have been shown to elicit immunogenicity by inducing immunogenic cell death (ICD). However, ICD-based immunotherapy is restricted by the ITM limiting its efficacy in eliciting a long-term antitumor immune response, and by severe systemic toxicity. To address these challenges, nanomedicine-based drug delivery strategies have been exploited for improving cancer immunotherapy by boosting ICD of the tumor cells. Nanosized drug delivery systems are promising for increasing drug accumulation at the tumor site and codelivering ICD inducers and immune inhibitors to simultaneously elicit the immune response and relieve the ITM. This review highlights the recent advances in nanomedicine-based immunotherapy utilizing ICD-based approaches. A perspective on the clinical translation of nanomedicine-based cancer immunotherapy is also provided.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41401-020-0400-z

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic of nanoparticle-mediated ICD for synergistic cancer immunotherapy. After overcoming pathophysiological barriers, multifunctional nanoparticles composed of ICD inducers and immune inhibitors induce tumor cell death via immunogenic pathways. The DAMPs released by dying cells play a crucial role in modulating the immunogenicity of the tumor microenvironment, including promoting the recruitment of APCs through tumor cell-derived secreted ATP and HMGB1 and facilitating DC maturation. Subsequently, activated DCs prime T cells, enabling CTLs to kill tumor cells via IFN-γ-dependent mechanisms.
Fig. 1 Schematic of nanoparticle-mediated ICD for synergistic cancer immunotherapy. After overcoming pathophysiological barriers, multifunctional nanoparticles composed of ICD inducers and immune inhibitors induce tumor cell death via immunogenic pathways. The DAMPs released by dying cells play a crucial role in modulating the immunogenicity of the tumor microenvironment, including promoting the recruitment of APCs through tumor cell-derived secreted ATP and HMGB1 and facilitating DC maturation. Subsequently, activated DCs prime T cells, enabling CTLs to kill tumor cells via IFN-γ-dependent mechanisms.CC BY · PubMed Central
Fig. 2 Schematic of OXA-loaded DHA NCPs (OxPt/DHAs) with synergistic antitumor activity by inducing ICD. a Chemical structure and synergistic mechanism of tumor inhibition; b Confocal images of cell surface localization of CRT upon exposure to OxPt/DHAs; c. Tumor growth over time with OxPt/DHAs or combination therapy with checkpoint blockade (anti-PD-L1) in a mouse model of CT26 colorectal tumor. Adapted with permission from [44]. Copyright (2019) Nature Publishing Group.
Fig. 2 Schematic of OXA-loaded DHA NCPs (OxPt/DHAs) with synergistic antitumor activity by inducing ICD. a Chemical structure and synergistic mechanism of tumor inhibition; b Confocal images of cell surface localization of CRT upon exposure to OxPt/DHAs; c. Tumor growth over time with OxPt/DHAs or combination therapy with checkpoint blockade (anti-PD-L1) in a mouse model of CT26 colorectal tumor. Adapted with permission from [44]. Copyright (2019) Nature Publishing Group.CC BY · PubMed Central
Fig. 3 Schematic illustration of shedding prodrug vesicles for cancer immunotherapy. a The preparation procedure for enzyme-activatable prodrug vesicles (EAPV) designed to codeliver PEGylated PS and an IDO-1 inhibitor (NLG919); b The mechanisms by which EAPVs enhance antitumor efficacy via synergic triggering of ICD and combating IDO-1-mediated adaptive immune resistance; c Immunofluorescence image of CRT expressed on the surface of tumor cells in the CT26 tumor xenograft model (scale bar = 50 μm); d Immunofluorescence image of HMGB1 release from tumor cells in the CT26 tumor xenograft model (scale bar = 25 μm); e The ratio of mature DCs in tumor-draining lymph nodes; f The number of intratumor infiltrating T lymphocytes in tumor tissue; g Kyn to Trp molar ratio determined for the CT26 tumor tissue; and h Tumor growth curves of the CT26 xenograft tumors. Adapted with permission from [86]. Copyright (2019) American Chemical Society.
Fig. 3 Schematic illustration of shedding prodrug vesicles for cancer immunotherapy. a The preparation procedure for enzyme-activatable prodrug vesicles (EAPV) designed to codeliver PEGylated PS and an IDO-1 inhibitor (NLG919); b The mechanisms by which EAPVs enhance antitumor efficacy via synergic triggering of ICD and combating IDO-1-mediated adaptive immune resistance; c Immunofluorescence image of CRT expressed on the surface of tumor cells in the CT26 tumor xenograft model (scale bar = 50 μm); d Immunofluorescence image of HMGB1 release from tumor cells in the CT26 tumor xenograft model (scale bar = 25 μm); e The ratio of mature DCs in tumor-draining lymph nodes; f The number of intratumor infiltrating T lymphocytes in tumor tissue; g Kyn to Trp molar ratio determined for the CT26 tumor tissue; and h Tumor growth curves of the CT26 xenograft tumors. Adapted with permission from [86]. Copyright (2019) American Chemical Society.CC BY · PubMed Central
Fig. 4 Schematic of LINC for cancer immunotherapy. a The chemical structures and self-assembly process of the LINC; b The mechanisms of NIR light-inducible nanoparticles that induce ICD and reprogram the immunosuppressive tumor microenvironment; c CRT expression; d Intratumoral infiltration of CD8+ T cells; and hematoxylin and eosin (H&E) staining of the lung sections collected from the (e) saline and (f) LINCL-treated mouse groups, respectively. Adapted with permission from [88]. Copyright (2019) John Wiley & Sons, Inc.
Fig. 4 Schematic of LINC for cancer immunotherapy. a The chemical structures and self-assembly process of the LINC; b The mechanisms of NIR light-inducible nanoparticles that induce ICD and reprogram the immunosuppressive tumor microenvironment; c CRT expression; d Intratumoral infiltration of CD8+ T cells; and hematoxylin and eosin (H&E) staining of the lung sections collected from the (e) saline and (f) LINCL-treated mouse groups, respectively. Adapted with permission from [88]. Copyright (2019) John Wiley & Sons, Inc.CC BY · PubMed Central
Fig. 5 Schematic of sHDL-DOX to enhance cancer immunotherapy by combining ICD and αPD-1. a The chemical structure and self-assembly process of a sHDL; b The mechanism of sHDL-triggered ICD-mediated antitumor immunity synergized with ICB. The level of CRT cell surface expression in c CT26 and d MC38 tumor models; e tumor volume over time and f Lung metastasis in CT26 tumor-bearing mice. Adapted with permission from [91]. Copyright (2019) Science Publishing Group.
Fig. 5 Schematic of sHDL-DOX to enhance cancer immunotherapy by combining ICD and αPD-1. a The chemical structure and self-assembly process of a sHDL; b The mechanism of sHDL-triggered ICD-mediated antitumor immunity synergized with ICB. The level of CRT cell surface expression in c CT26 and d MC38 tumor models; e tumor volume over time and f Lung metastasis in CT26 tumor-bearing mice. Adapted with permission from [91]. Copyright (2019) Science Publishing Group.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Research works printed but not linked: 2

  1. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61. · DOI · Paper page
  2. Gao J, Wang WQ, Yu HJ. Acid-activatable polymeric drug delivery systems for cancer therapy. Acta Pharm Sin. 2019;50:1156–66.

Cited by

See all 203

Metadata

Authors
Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J.
Affiliations
  • Chinese Academy of Sciences (CN)
  • UNSW Sydney (AU)
Venue
Acta Pharmacologica Sinica
Published
2020-04-21
Volume
41
Issue
7
Pages
986-994
ISSN
  • 0253-9756 (ISSN-L)
  • 1671-4083
  • 1745-7254
OpenAlex
W3016713923
Cited by
203
References
96
Citations by year
2026: 65 · 2025: 25 · 2024: 25 · 2023: 28 · 2022: 29 · 2021: 22 · 2020: 8
FWCI
1.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Pharmacologica Sinica (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
Funders
  • University of New South Wales
  • National Natural Science Foundation of China (31900990, 51873228, 81521005, 31671024)
  • Chinese Academy of Sciences (2014218)
  • Youth Innovation Promotion Association of the Chinese Academy of Sciences (2014218)
  • Youth Innovation Promotion Association
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immunogenic cell death, cancer immunotherapy, nanomedicine, tumor microenvironment, immunosuppression, immune checkpoint inhibitors, solid tumors, clinical translation
MeSH terms
Immunogenic Cell Death, Antineoplastic Agents, Humans, Immunotherapy, Neoplasms, Photochemotherapy, Drug Delivery Systems, Nanomedicine, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41401-020-0400-z
The paper
Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J. (2020). Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-020-0400-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.